Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novartis Ag (NVS)

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Ocular Drug Delivery Technology Market : Discussion Of Market Drivers, Key Vendors And Challenges With Forecast To 2024

Ocular drug delivery refers to the treatment of ophthalmic diseases. Ophthalmic diseases affect various parts of the eye anatomy, are specified on the basis of their position namely, anterior segment and...

CLSD : 1.11 (unch)
NVS : 89.86 (+0.64%)
PFE : 36.60 (-1.00%)
VRX.TO : 30.80 (-3.33%)
Theragnostics Strengthens Leadership Team with Two Key Appointments

Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces two strategic hires to its leadership team with the appointment of Dr Daniel Stevens...

NVS : 89.86 (+0.64%)
Top Analyst Reports for Microsoft, Novartis & Novo Nordisk

Top Analyst Reports for Microsoft, Novartis & Novo Nordisk

VMW : 165.83 (-1.27%)
TSLA : 346.11 (-1.09%)
NVS : 89.86 (+0.64%)
NVO : 57.64 (+0.96%)
MSFT : 147.31 (+0.16%)
GD : 184.72 (-0.30%)
Novartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace

Novartis announced today it has partnered with Grammy, Tony and Emmy award-winning singer, songwriter, actress and activist Cyndi Lauper to launch PsO at Work, a national campaign to bring to life the...

NVS : 89.86 (+0.64%)
Novartis in Canada named to 2019 Best Workplaces(TM) in Quebec

Novartis Pharmaceuticals Canada Inc. has been named to the 2019 list of Best Workplaces in Quebec. This follows a thorough and independent analysis conducted by Great Place to Work(®) Institute Canada,...

NVS : 89.86 (+0.64%)
LifeMax Receives Orphan Drug Designation From the European Commission for LM-030 for the Treatment of Netherton Syndrome

LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating rare diseases with few or no therapeutic options, today announced that the European Commission granted orphan drug designation...

IPXL : 18.30 (unch)
NVS : 89.86 (+0.64%)
Varicella Zoster Infection Treatment Market Reflecting a CAGR of 4.2% During the Forecast Period 2017 - 2027

Future Market Insights (FMI) has published a new report on the varicella zoster infection treatment market titled comprises two main types namely varicella chickenpox and herpes zoster. Varicella is a...

ABT : 84.22 (-0.14%)
GSK : 44.66 (+0.31%)
NVS : 89.86 (+0.64%)
PFE : 36.60 (-1.00%)
TEVA : 9.78 (+1.77%)
VRX.TO : 30.80 (-3.33%)
At CAGR 2.5% Inflammatory Bowel Disease Treatment Market 2019 Growing Globally, Industry Size, Share Leaders, Current Trends, Status by Major Key Vendors, and Drivers by Forecast To 2023

ABBV : 86.66 (+0.25%)
AGN : 181.60 (-0.20%)
NVS : 89.86 (+0.64%)
PFE : 36.60 (-1.00%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
World Dry Eye Medication Market Report 2020: Major Players are Novartis, Allergan, Otsuka, Santen Pharmaceutical and Auven Therapeutics - ResearchAndMarkets.com

The "Dry Eye Medication Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering.

AGN : 181.60 (-0.20%)
NVS : 89.86 (+0.64%)
Roche's SMA Drug Meets Primary Endpoint in Pivotal Study

Roche's (RHHBY) risdiplam meets primary endpoint in SUNFISH study in SMA patients.

NVS : 89.86 (+0.64%)
RHHBY : 37.6000 (+0.29%)
BIIB : 281.89 (-3.26%)
PTCT : 43.00 (+2.94%)
Flagship Pioneering Appoints Prakash Raman, Ph.D. as Senior Partner and Chief Business Development Officer

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Prakash Raman, Ph.D. to the post of Senior Partner and the newly created role of Chief Business Development...

NVS : 89.86 (+0.64%)
AXLA : 3.83 (-3.04%)
DNLI : 15.15 (+0.87%)
EVLO : 6.33 (-3.06%)
KLDO : 6.11 (unch)
MRNA : 18.25 (+1.45%)
RUBY : 9.84 (-2.19%)
MCRB : 3.69 (+0.54%)
SYRS : 5.24 (+4.38%)
Evotec SE Reports First Nine-Month 2019 Results and Corporate Updates

Evotec SE Reports First Nine-Month 2019 Results and Corporate Updates

CELGZ : 0.48 (unch)
NVS : 89.86 (+0.64%)
NVO : 57.64 (+0.96%)
GNHAF : 153.9906 (-3.55%)
Sandoz presents real-world data showing effectiveness of Erelzi(R) (etanercept-szzs) in rheumatic disease treatment

- Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting

NVS : 89.86 (+0.64%)
New Novartis PREVENT data show Cosentyx(R) delivers early relief in axial spondyloarthritis

- 42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores through Week 16; improvements continued through Week 52[1]

NVS : 89.86 (+0.64%)
Results for Bimagrumab in Obesity and Type 2 Diabetes Presented by MorphoSys's Partner

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 11, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Novartis presented phase 2 results...

MOR : 26.33 (+0.61%)
NVS : 89.86 (+0.64%)
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

NVO : 57.64 (+0.96%)
NVS : 89.86 (+0.64%)
SNY : 45.62 (-0.93%)
AGN : 181.60 (-0.20%)
JNJ : 131.27 (-0.06%)
Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day

Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day

CHRW : 74.63 (-1.15%)
CHGG : 36.05 (+2.01%)
NVS : 89.86 (+0.64%)
BUD : 79.28 (+0.25%)
TLRY : 20.93 (-2.97%)
Novartis' Generics Unit to Buy Aspen's Japanese Operations

Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.

MRK : 84.82 (+0.83%)
BMY : 58.79 (+0.69%)
NVS : 89.86 (+0.64%)
GSK : 44.66 (+0.31%)
Sandoz announces agreement to acquire Aspen's Japanese operations and associated assets, strengthening position in world's third largest generics market

Sandoz announces agreement to acquire Aspen's Japanese operations and associated assets, strengthening position in world's third largest generics market

NVS : 89.86 (+0.64%)
ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG - NVS

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may...

NVS : 89.86 (+0.64%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.71 , AIZ +0.69 , SBAC +4.93 , SO +1.22 , WELL +0.81
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar